How many 8-K filings has Contineum Therapeutics, Inc. filed?

Contineum Therapeutics, Inc. (CTNM) has 12 8-K (Current Event Report) filings on record, spanning Apr 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Contineum Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Contineum Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Contineum Therapeutics, Inc. (CTNM) — 8-K Filings

All 8-K filings from Contineum Therapeutics, Inc.. Browse 12 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (12)

Contineum Therapeutics Files 8-K — Dec 15, 2025 Risk: medium
Contineum Therapeutics, Inc. filed an 8-K on December 15, 2025, reporting on events that occurred on December 11, 2025. The filing indicates a material definiti
Contineum Therapeutics Files 8-K — Dec 11, 2025 Risk: low
Contineum Therapeutics, Inc. filed an 8-K on December 11, 2025, reporting on events that occurred on December 8, 2025. The filing primarily concerns financial s
8-K Filing — Nov 20, 2025
Contineum Therapeutics Files 8-K — Sep 18, 2025 Risk: low
Contineum Therapeutics, Inc. filed an 8-K on September 18, 2025, reporting on various events including a Regulation FD Disclosure, Other Events, and Financial S
Contineum Therapeutics Files 8-K on Security Holder Vote Matters — Jun 26, 2025 Risk: low
On June 26, 2025, Contineum Therapeutics, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, formerly known
Contineum Therapeutics Files 8-K — Apr 28, 2025 Risk: low
Contineum Therapeutics, Inc. filed an 8-K on April 28, 2025, reporting other events and financial statements. The company, formerly known as Pipeline Therapeuti
Contineum Therapeutics: Leadership Changes and New Directors — Mar 17, 2025 Risk: medium
Contineum Therapeutics, Inc. announced on March 14, 2025, the departure of Dr. Jonathan Leaman as Chief Medical Officer. The company also announced the election
Contineum Therapeutics Files 8-K on Financials — Aug 13, 2024 Risk: low
Contineum Therapeutics, Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing includes financial stat
Contineum Therapeutics Appoints New CMO, CSO, and Directors — Jun 24, 2024 Risk: medium
Contineum Therapeutics, Inc. announced on June 21, 2024, the appointment of Dr. Jonathan Leipsic as Chief Medical Officer and Dr. David E. Cohen as Chief Scient
Contineum Therapeutics Appoints New CMO and CSO — May 31, 2024 Risk: medium
Contineum Therapeutics, Inc. announced on May 24, 2024, the appointment of Dr. Jonathan Leipsic as Chief Medical Officer and Dr. David E. Johnson as Chief Scien
Contineum Therapeutics Appoints New CMO & CSO — May 20, 2024 Risk: medium
Contineum Therapeutics, Inc. announced on May 20, 2024, the appointment of Dr. Jonathan Leipsic as Chief Medical Officer and Dr. David E. R. Brown as Chief Scie
Contineum Therapeutics Files 8-K for Bylaws and Financials — Apr 9, 2024 Risk: low
Contineum Therapeutics, Inc. filed an 8-K on April 9, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The compan

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX